Treatment outcome according to tumor RAS mutation status in OPUS study patients with metastatic colorectal cancer (mCRC) randomized to FOLFOX4 with/without cetuximab.
Carsten Bokemeyer
Consultant or Advisory Role - Merck Serono
Honoraria - Merck Serono
Claus-Henning Kohne
Consultant or Advisory Role - EMA (London)
Honoraria - Bayer; Bristol-Myers Squibb; Merck KGaA; Roche
Fortunato Ciardiello
Honoraria - Bayer; Merck Serono
Research Funding - AstraZeneca; Bayer; Merck Serono
Heinz-Josef Lenz
Consultant or Advisory Role - Bristol-Myers Squibb; EMD Serono; Merck KGaA
Honoraria - Bristol-Myers Squibb; EMD Serono; Merck KGaA
Research Funding - Bristol-Myers Squibb; EMD Serono
Volker Heinemann
Consultant or Advisory Role - Amgen; Merck KGaA; Roche; Sanofi
Honoraria - Amgen; Merck KGaA; Roche; Sanofi
Research Funding - Amgen; Merck KGaA; Roche; Sanofi
Ute Klinkhardt
Employment or Leadership Position - Merck KGaA
Frank Beier
Employment or Leadership Position - Merck KGaA
Klaus Duecker
Employment or Leadership Position - Merck Serono
Other Remuneration - Merck Serono
Sabine Tejpar
Consultant or Advisory Role - Merck Serono
Honoraria - Merck Serono